Adefovir dipivoxil in chronic hepatitis B infection

Bibliography

• KRAMATA P, VOTRUBA I, OTOVA B,HOLY A: Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta, and epsilon. Ma Pharmacol (1996) 49:1005–1011.
   PubMed Web of Science ®Google Scholar
• CUNDY KC: Clinical pharmacokinetics ofthe antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. (1999) 36:127–143.
   PubMed Web of Science ®Google Scholar
• Gilead Sciences, Inc.: Hepsera® (adefovir dipivoxil) full prescribing information. Foster City, CA, USA (2002).
   Google Scholar
• KEARNEY B, KNIGHT W, CURRIE G et al.: Adeofivr dipivoxil safety and pharmacokinetics in subjects with hepatitis B virus infection and in healthy subjects. Hepatol (2002) 36\(Suppl. 1):100.
   Google Scholar
• KNIGHT W, HAYASHI S, BENHAMOU Y et al: Dosing guidelines for adefovir dipivoxil in the treatment of HBV infected patients with renal or hepatic impairment. J. Hepatol (2002) 36\(Suppl. 1):136.
   Google Scholar
• FISHER EJ, CHALONER K, COHN DL et al.: The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS(2001) 15:1695–1700.
   PubMed Web of Science ®Google Scholar
• RAY AS, VELA JE, OLSON L, FRIDLAND A: Effective metabolism and long intracellular half life of the anti-hepatitis B agent adefovir in hepatic cells. Biochem. Pharmacol (2004) 68(9):1825–1831.
   PubMedGoogle Scholar
• •A report on the most up-to-date information on the pharmacokinetics of adefovir dipivoxil.
   Google Scholar
• TORRESI J, LOCARNINI SA: New therapeutic strategies in the treatment of hepatitis B virus infection. Expert Opin. Invest. Drugs (1999) 8:289–305.
   PubMedGoogle Scholar
• TORRESI J, LOCARNINI S: Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology(2000) 118(2 Suppl. 1):S83–S103.
   Google Scholar
• CALIO R, VILLANI N, BALESTRA E et al.: Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antivir: Res. (1994) 23:77–89.
   PubMed Web of Science ®Google Scholar
• COOKSLEY H, CHOKSHI S, WEDEMEYER H et al.: Hepatitis B virus-specific T-cell reactivity during adefovir dipivoxil (ADV) treatment: a multicenter, controlled study. Hepatology (2002) 36(4 Pt 2):633A.
   Google Scholar
• MAILLIARD ME, GOLLAN JL: Suppressing hepatitis B without resistance - so far, so good. N. Engl. J. Med. (2003) 348:848–850.
   PubMed Web of Science ®Google Scholar
• YOKOTA T, KONNE K, SHIGETA S et al.: Inhibitory effects of acyclic nucleoside phosphonate analogues on hepatitis B virus DNA synthesis in HBG11 cells. Antiviral Chem. Chemother. (1994) 5:57–63.
   Web of Science ®Google Scholar
• HEIJTINK RA, DE WILDE GA, KRUINING J et al.: Inhibitory effect of 9-(2-phosphonylemthoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antivir: Res. (1993) 21:141–153.
   PubMed Web of Science ®Google Scholar
• HEIJTINK RA, KRUINING J, DE WILDE GA et al.: Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob. Agents Chemother. (1994) 38:2180–2182.
   Google Scholar
• KRUINING J, HEIJTINK RA, SCHALM SW: Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment. Hepatol (1995) 22:263–267.
   Google Scholar
• YOKOTA T, MOCHIZUKI S, KONNO K et al.: Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis. Antimicrob. Agents Chemother. (1991) 35:394–397.
   PubMedGoogle Scholar
• NAESENS L, SNOECK R, ANDREI G et al.: HPMPC (cidofovir), PMEA (adefovir), and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antivir: Chem. Chemother: (1997) 8:1–23.
   Web of Science ®Google Scholar
• NICOLL A, COLLEDGE D, TOOLE J et al.: Inhibition of duck hepatitis B virus replication by 942-phosphonyl-methoxyethylladenine, an acyclic phosphonate nucleoside analogue. Antimicrob. Agents Chemother. (1998) 42:3130–3135.
   PubMed Web of Science ®Google Scholar
• CULLEN JM, LI DH, BROWN C et al:Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. Antimicrob. Agents Chemother. (2001) 45:2740–2745.
   PubMed Web of Science ®Google Scholar
• GILSON RJ, CHOPRA KB, NEWELL AM et al.: A placebo-controlled Phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J. Viral Hepat. (1999) 6:387–395.
   PubMed Web of Science ®Google Scholar
• JEFFERS L, HEATHCOTE E, WRIGHT T et al.: A Phase II dose-ranging, placebo-controlled trial of adefovir dipivoxil for the treatment of chronic hepatitis B virus infection. Antiviral Res. (1998) 37:A197.
   Google Scholar
• MARCELLIN P, CHANG TT, LIM SG et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl. I Med. (2003) 348:808–816.
   PubMed Web of Science ®Google Scholar
• ••The landmark study of the efficacy of adefovir dipivoxil on HBeAg-positive patients.
   Google Scholar
• HADZIYANNIS SJ, TASSOPOULOS NC, HEATHCOTE et al: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl. I Med. (2003) 348:800–807.
   PubMed Web of Science ®Google Scholar
• ••The landmark study of the efficacy ofadefovir dipivoxil on anti-HBe-positive patients.
   Google Scholar
• WAI CT, CHU CJ, HUSSAIN M, LOK AS: HBV genotype B is associated with better response to interferon therapy in HBeAg (+) chronic hepatitis than genotype C. Hepatology(2002) 36:1425–1430.
   PubMed Web of Science ®Google Scholar
• KAO JH, WU NH, CHEN PJ, LAI MY, CHEN DS: Hepatitis B genotypes and the response to interferon therapy. J. Hepatol (2000) 33:998–1002.
   PubMed Web of Science ®Google Scholar
• YUEN ME WONG DKH, SABLON E et al.: Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir: Ther. (2003) 8:531–534.
   Google Scholar
• ••The first comparative trial of larnivudinetreatment in hepatitis B patients infected with genotypes B and C.
   Google Scholar
• WESTLAND C, DLANEY W IV, YANG H et al.: Hepatitis B virus genotypes and virologic response in 694 patients in Phase III studies of adefovir dipivoxil. Gastroenterology (2003) 125:107–116.
   PubMed Web of Science ®Google Scholar
• ••The first report on the efficacy of adefovirdipivoxil on different HBV genotypes.
   Google Scholar
• MARCELLIN P, CHANG TT, LIM SG et al.: Adefovir dipivoxil (ADV) 10 mg for the treatment of patients with HBeAg+ chronic hepatitis B: continued efficacy beyond 48 weeks. Hepatology (2002) 36(Pt 2):373A.
   Google Scholar
• HADZIYANNIS S, TASSOPOULOS N, HEATHCOTE J et al.: Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B. J. Hepatol. (2003) 38\(Suppl. 2):143.
   Google Scholar
• HADZIYANNIS S, TASSOPOULOS N, CHANG TT et al.: Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTSES). Hepatol. (2004) 40\(Suppl. 1):17.
   Google Scholar
• CHANG TT, SHIFFMAN M, TONG M et al.: Durability of HBeAg seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB). I Hepatol. (2004) 40\(Suppl. 1):126.
   Google Scholar
• SHIFFMAN M, MARCELLIN P, JEFFERS L et al.: HBsAg seroconversion in adefovir dipivoxil (ADV) treated chronic hepatitis B (CHB) patients. I Hepatol. (2004) 40\(Suppl. 1):17.
   Google Scholar
• ANGUS P, VAUGHAN R, XIONG S et al.: Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology (2003) 125:292–297.
   PubMed Web of Science ®Google Scholar
• •The first in vivo study on the sensitivity of adefovir dipivoxil resistant HBV to lamivudine treatment.
   Google Scholar
• WESTLAND CE, YANG H, DELANEY WE IV et al.: Week 48 resistance surveillance in two Phase III clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology (2003) 38:96–103.
   Google Scholar
• SUNG JJY, LAI JY, ZEUZEM S et al.: A randomized double-blind phse II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): week 52 analysis. Hepatol. (2003) 38\(Suppl. 2):25.
   Google Scholar
• PERRILLO R, HANN HW, MUTIMER D et al.: Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology (2004) 126:81–90.
   PubMed Web of Science ®Google Scholar
• •One of the two controlled trials on the efficacy of adefovir dipivoxil treatment for HBV with YMDD mutations.
   Google Scholar
• PETERS MG, HANN HW, MARTIN P et al.: Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology(2004) 126:91–101.
   PubMed Web of Science ®Google Scholar
• •One of the two controlled trials on the efficacy of adefovir dipivoxil treatment for HBV with YMDD mutations.
   Google Scholar
• SCHIFF ER, LAI CL, HADZIYANNIS S et al.: Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pm- and post-liver transplantation patients. Hepatology (2003) 38:1419–1427.
   PubMed Web of Science ®Google Scholar
• •The first trial of adefovir dipivoxil on pre-and post-liver transplantation of HBV infection.
   Google Scholar
• WERLE-LAPOSTOLLE B, BOWDEN S, LOCARNINI S et al.: Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 126:1750–1758.
   PubMed Web of Science ®Google Scholar
• BENHAMOU Y, THIBAULT V, VIG P et al.: Long term treatment with adefovir dipivoxil (ADV) for three years in patients with lamivudine-resistant (LAM-R) HBV and HIV co-infection results in significant and sustained clinical improvement. Hepatology (2003) 38(4 Suppl. 1):714A.
   Google Scholar